Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Stock Down 2.4 %

EVGN stock opened at $1.65 on Friday. The company has a market cap of $8.85 million, a price-to-earnings ratio of -0.37 and a beta of 1.36. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40. The business has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $3.45.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.